Effectiveness of natriuretic peptide-guided treatment of chronic heart failure. A meta-analysis

被引:2
|
作者
Gamino-Arroyo, Ana-Estela [1 ]
Prado-Galbarro, Francisco-Javier [2 ,3 ,4 ]
Garcia-Perez, Sonia [4 ,5 ]
Sanchez-Piedra, Carlos [4 ]
机构
[1] Hosp Infantil Mexico Dr Federico Gomez, Unidad Infectol, Ciudad De Mexico, Mexico
[2] Inst Nacl Enfermedades Resp, Ctr Invest Enfermedades Infecciosas, Ciudad De Mexico, Mexico
[3] Inst Nacl Salud Publ, Unidad Salud Reprod, Cuernavaca, Morelos, Mexico
[4] Inst Salud Carlos III, Agencia Evaluac Tecnol Sanitarias, Madrid, Spain
[5] REDISSEC, Unidad Invest, Madrid, Spain
来源
ARCHIVOS DE CARDIOLOGIA DE MEXICO | 2018年 / 88卷 / 03期
关键词
Heart failure; Natriuretic peptide; Meta-analysis; Therapy; NT-proBNP; Mexico;
D O I
10.1016/j.acmx.2017.02.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate the efficacy of natriuretic peptide (NP)-guided therapy compared to clinically-guided therapy in reducing mortality and hospital admissions in chronic heart failure (HF) patients. Methods: Randomised clinical trials (RCT) were selected through a systematic review. Four meta-analyses were conducted for the outcomes of overall mortality, HF-related mortality, overall hospital admissions, and HF-related hospital admissions. Heterogeneity between studies and publication bias were also assessed. Results: Nine RCTs were found with a total of 1914 patients. NP-guided therapy significantly reduced overall mortality and HF-related hospital admissions. No significant results were found for HF-related mortality and overall hospital admissions. Some clinical heterogeneity regarding interventions performed was found between studies. Publication bias was found for HF-related and overall hospital admissions. Conclusions: NP-guided therapy seems to improve outcomes compared to clinically-guided therapy. However, heterogeneity found between interventions might reduce the generalisation of these results. Specific interventions of the clinical trials should be examined when making recommendations regarding NP-guided therapy. (C) 2017 Instituto Nacional de Cardiologia Ignacio Chavez. Published by Masson Doyma Mexico S.A.
引用
收藏
页码:171 / 177
页数:7
相关论文
共 50 条
  • [41] B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data
    Pufulete, Maria
    Maishman, Rachel
    Dabner, Lucy
    Higgins, Julian P. T.
    Rogers, Chris A.
    Dayer, Mark
    MacLeod, John
    Purdy, Sarah
    Hollingworth, William
    Schou, Morten
    Anguita-Sanchez, Manuel
    Karlstrom, Patric
    Shochat, Michael Kleiner
    McDonagh, Theresa
    Nightingale, Angus K.
    Reeves, Barnaby C.
    SYSTEMATIC REVIEWS, 2018, 7
  • [42] B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data
    Maria Pufulete
    Rachel Maishman
    Lucy Dabner
    Julian P. T. Higgins
    Chris A. Rogers
    Mark Dayer
    John MacLeod
    Sarah Purdy
    William Hollingworth
    Morten Schou
    Manuel Anguita-Sanchez
    Patric Karlström
    Michael Kleiner Shochat
    Theresa McDonagh
    Angus K. Nightingale
    Barnaby C. Reeves
    Systematic Reviews, 7
  • [43] Is B-type natriuretic peptide-guided heart failure management cost-effective?
    Morimoto, T
    Hayashino, Y
    Shimbo, T
    Izumi, T
    Fukui, T
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2004, 96 (02) : 177 - 181
  • [44] Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure.
    Colucci, WS
    Elkayam, U
    Horton, DP
    Abraham, WT
    Bourge, RC
    Johnson, AD
    Wagoner, LE
    Givertz, MM
    Liang, CS
    Neibaur, M
    Haught, WH
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (04): : 246 - 253
  • [45] B-type natriuretic peptide guided treatment of heart failure and all cause mortality: an individual patient data meta-analysis
    Troughton, R.
    Brunner-La Rocca, H. P.
    Frampton, C. M.
    Berger, R.
    Persson, H.
    O'Connor, C. M.
    Pinto, Y.
    EUROPEAN HEART JOURNAL, 2011, 32 : 495 - 495
  • [46] B-type natriuretic peptide or amino-terminal pro-B-type natriuretic peptide-guided treatment of heart failure: what is the next STEP?
    Troughton, Richard W.
    Nicholls, M. Gary
    EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (10) : 1046 - 1048
  • [47] Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome
    Karlstrom, Patric
    Alehagen, Urban
    Boman, Kurt
    Dahlstrom, Ulf
    EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (10) : 1096 - 1103
  • [48] Natriuretic Peptide Guided Heart Failure Management
    Mohammed, Asim A.
    Januzzi, James L., Jr.
    CURRENT CLINICAL PHARMACOLOGY, 2009, 4 (02): : 87 - 94
  • [49] Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches
    Stienen, Susan
    Bhatt, Ankeet
    Ferreira, Joao Pedro
    Vaduganathan, Muthiah
    Januzzi, James
    Adams, Kirkwood
    Tardif, Jean-Claude
    Rossignol, Patrick
    Zannad, Faiez
    HEART FAILURE REVIEWS, 2021, 26 (01) : 11 - 21
  • [50] Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches
    Susan Stienen
    Ankeet Bhatt
    João Pedro Ferreira
    Muthiah Vaduganathan
    James Januzzi
    Kirkwood Adams
    Jean-Claude Tardif
    Patrick Rossignol
    Faiez Zannad
    Heart Failure Reviews, 2021, 26 : 11 - 21